3 Nitrogen-containing bisphosphonates (N-BPs) are the standard treatment for osteoporosis and several other bone diseases 11, 12 . Certain N-BPs (pamidronate (Aredia®), zoledronate (Zometa®)) are also routinely prescribed to prevent skeletal complications in patients with multiple myeloma and with bone metastases from other malignancies, including breast and prostate cancer 13 . However, because N-BPs cause rare yet serious side-effects, such as atypical fractures and osteonecrosis of the jaw, many patients avoid taking them [5] [6] [7] 11 , causing the number of prescriptions to plummet over 50% in the last decade 7, 14 . Thus, there is a sizeable and growing need to better understand the genetic factors that might underlie the onand off-target clinical effects of the N-BPs.
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understanding of the molecular mechanisms by which N-BPs regulate the major bone cell types would be improved by further studies.
To provide insight into the mechanism(s) of N-BPs action, we performed a genetic screen to identify human genes required for the anti-proliferative effects of N-BPs (Fig. 1a) . We made use of a largely haploid human cell line of myeloid origin (KBM7, a.k.a. HAP1) to generate a library of retroviral gene trap mutants 25 , and then selected for clones which are resistant to cytotoxic levels of alendronate. The advantages of this cell line for genetic screening include: 1) each gene is present as a single copy, enabling gene inactivation (except those genes on chromosome 8); and 2) KBM7 cells are human and of the hematopoietic lineage, increasing the likelihood that any genes we identify could be relevant to the natural context for N-BPs, the bones of human patients 26 . Using this haploid approach, we identified a poorly characterized gene, ATRAID, a.k.a., APR3/C2orf28 27 , as the gene most significantly enriched for insertions in alendronate resistant cells compared to untreated cells (Fig. 1b , and Supplementary Table 1a ).
Other genes identified in our alendronate haploid screen (SNTG1, PLCL1, and EPHB1) have been previously connected to N-BP action on bone cells and/or human bone diseases [28] [29] [30] . To systematically evaluate all "hits" we identified (i.e., the 185 genes with FDR p-value < 0.05, see Fig. 1b ), we developed a computational approach utilizing a molecular biology-optimized version of PubMed (currently at ~27M records) to assess to what extent our haploid screen identified genes were cited as relevant to human studies that focus on bone (see "PubMed citation analysis" in the Methods section for details). We asked whether our alendronate haploid screen hits were mentioned in publications co-occurring with the term "bone" vs. other tissues along with identifiers of genome-wide screening, namely the strings, "GWAS" or "genome-wide" (Fig.   1c ). Indeed, our alendronate screen hits were enriched in publications co-mentioning "bone" and genome-wide studies compared to control gene sets (Fig. 1d, Supplementary Table 1b ). This suggests that the KBM7 cells we used and our screening approach with alendronate can identify genes relevant to human bone.
N-BPs target FDPS in the mevalonate, a.k.a. cholesterol biosynthesis, pathway (Fig. 1e) . The statins, which are cholesterol lowering drugs for heart health 31 , are a widely used drug class that, like the N-BPs, target the mevalonate pathway (Fig. 1e ). Therefore, it seemed possible that ATRAID and other genes we identified with alendronate in our haploid screen might also score highly with statins. In haploid screening for genes which when inactivated conferred resistance to two statins, simvastatin and lovastatin (a.k.a., mevinolin), we didn't detect ATRAID, though we did identify several novel factors including WT1 that were common to both statins ( Fig. 1f , Supplementary Table 1a ). Because FDPS is essential [32] [33] [34] , and thus wouldn't be detected with our haploid approach, we employed a knockdown-based approach, CRISPRi 35 as a complementary strategy (Fig. 1g ). Using CRISPRi, we identified both ATRAID and FDPS among the top 200 hits with alendronate 36 , but not with several other clinical and experimental drugs including ones that regulate the mevalonate pathway ( Fig. 1h and Supplementary Table   1a ) [37] [38] [39] . Taken together with our haploid screening and recent work on FDPS by Horlbeck et al. 40 , this data suggests ATRAID and FDPS might be part of a unique pathway separable from that targeted by the statins and other drugs.
These genome-wide screens were in cells, so we sought to test whether the genes we identified might be relevant in patients treated with N-BPs. We performed exome sequencing of osteoporotic patients who experienced atypical femoral fractures (AFF) when taking N-BPs and compared their DNA with osteoporotic patients who didn't suffer this side effect (Fig. 1i) . We also analyzed two published gene expression datasets involving patients who had taken N-BPs:
multiple myeloma patients who did or did not suffer osteonecrosis of the jaw (ONJ) when taking N-BPs 41 ; and breast cancer patients with bone marrow disseminated tumor cells (DTC) which 6 reoccurred or the patient died less than 1000 days vs. greater than 2500 days following initiation of zolendronate treatment 42 ( Fig. 1i , and Supplementary Fig. 1c) . In comparing our cell-based CRISPRi screen with the three patient-based datasets, ATRAID was amongst the 30 genes that scored in all datasets ( Fig. 1j and k) . FDPS and IDI1, which produces a metabolite, dimethylallylpyrophosphate (DMAPP) required for the synthesis of the major FDPS product, farnesyl pyrophosphate (FPP), were also differentially expressed and/or possessed coding variants only seen in the poor N-BP treatment outcome arms of several of the patient datasets ( Fig. 1k and Supplementary Fig. 1 ). Taken together, this suggests that FDPS and the novel factor, ATRAID, may influence N-BP responses in people.
Recently we identified another gene, SL37A3, that provides molecular details for how ATRAID connects to the N-BPs and FDPS 36 . However, because SLC37A3 wasn't amongst the 30 genes that scored in all the patient-and cell-based studies (Fig. 1i, j) , we focused our further characterization on ATRAID. ATRAID was originally identified as a gene whose mRNA expression is strongly induced by the ligand, all-trans retinoic acid 27 . ATRAID is conserved in chordates and contains a signal peptide, Toll-like-receptor leucine rich repeat, EGF-like domain, and a transmembrane domain ( Fig. 2a and Supplementary Fig. 2a ) 43, 44 . Importantly, the alendronate resistance phenotype of ATRAID deficient cells (ATRAID_GT1 (gene-trap1) and ATRAID_GT2 (gene-trap2)) was reversed by the re-introduction of wild-type ATRAID splice variant 2 (v2) or splice variant 3 (v3) cDNA, which differ in their N-termini ( Fig. 2d ). Lastly, ATRAID membrane targeting is required for the anti-proliferative effects of alendronate, as ATRAID deficient cells complemented with full-length ATRAID (v2) were sensitive to the cytotoxic effects of alendronate, whereas those expressing the membrane truncated form remained resistant ( Supplementary Fig. 2e ). Taken together, these data establish ATRAID as a genetic factor required for the growth inhibitory effects of alendronate.
N-BPs are part of a larger class of compounds known as bisphosphonates (BPs) that contain two phosphate moieties each joined to a carbon atom by a carbon-phosphorus bond 45 ( Fig. 2c ).
To determine whether the effects of ATRAID deficiency on alendronate resistance were specific to nitrogen-containing bisphosphonates, we tested the effect of several nitrogen-containing and non-nitrogen-containing bisphosphonates on wild-type and mutant ATRAID cells. Strikingly, ATRAID deficient cells were resistant to all nitrogen-containing bisphosphonates tested including alendronate, zoledronate, ibandronate and pamidronate, but were as sensitive to the non-nitrogen-containing bisphosphonates, etidronate and tiludronate, as control cells (Fig. 2d) .
Consistent with our haploid statin screens ( Supplementary Fig. 1a and Supplementary Table   1a) , ATRAID deficient cells were not resistant to the statin, lovastatin (Fig. 2e) . The lack of resistance of ATRAID-deficient cells to non-nitrogen-containing bisphosphonates and lovastatin suggests that the effects we observe are specific to nitrogen-containing bisphosphonates. This specificity is consistent with the observation that non-nitrogen-containing bisphosphonates and nitrogen-containing bisphosphonates have distinct mechanisms of action 45 .
To determine whether ATRAID is required for the reduction in protein prenylation observed upon N-BP treatment, we monitored the prenylation of several proteins, including the heat shock protein DnaJ (Hsp40) homolog HDJ-2, and the Ras family GTPase Rap1a 46 . Alendronate strongly inhibited prenylation of HDJ-2 and Rap1a in wild-type cells in a dose dependent manner, and had much less of an effect on prenylation of these proteins in ATRAID-deficient cells (Fig. 2f) . Furthermore, the inhibitory effect of alendronate on prenylation was rescued when 8 ATRAID cDNA variants (v2 and v3) were introduced ( Supplementary Fig. 2f ). We observed inhibition of prenylation resistance at N-BP doses where we did not see PARP-1 cleavage in ATRAID deficient cells, suggesting that ATRAID can mediate the effect on prenylation independent of apoptosis ( Supplementary Fig. 2f ). Thus, ATRAID functions upstream of FDPS and in total, these findings suggest that ATRAID is required for molecular responses to N-BPs.
N-BPs can affect numerous cell types when administered to intact mammals, therefore to evaluate the role of ATRAID in N-BPs responses, we inactivated ATRAID globally in mice 47 . We confirmed deletion of ATRAID exons 3-5 and determined that ATRAID homozygous deleted ATRAID KO mice (labeled KO, -/-) are viable but their body weight is mildly reduced compared with litter-matched derived, wild-type controls (labelled as WT, +/+) ( Supplementary Fig. 3a -c).
We confirmed that tail fibroblasts derived from ATRAID KO animals are resistant to the cytotoxic effects of alendronate ( Supplementary Fig. 3d , e).
Before studying the effects of the N-BPs in the context of ATRAID loss, we first characterized the basal role of ATRAID in bones. We determined that ATRAID mRNA expression was undetectable in the bones of ATRAID KO animals and that ATRAID KO mice had slightly smaller bones compared with litter-matched derived, wild-type control mice ( Supplementary Fig. 3f, g ).
To examine the effects of ATRAID on bone structure, we performed micro-computed tomography (µCT) analysis 48 . ATRAID deficiency did not significantly decrease either trabecular and cortical structural parameters ( Supplementary Fig. 3h , i). We measured bone strength using three-point bending tests 49 . Some measures, such as stiffness (Newtons/meter, N/m) and postyield displacement (a measure of bone fragility, in millimeters, m) were decreased by ATRAID deficiency, whereas others such, as yield load (the point where bone bending goes from elastic vs. plastic, in Newtons, N), were not significantly altered ( Supplementary Fig. 3j -l).
Osteoclasts release degradation products from C-terminal telopeptides of type I collagen (CTX-I) from bone into blood 50 , and levels of CTX-I in serum were unchanged in wild-type mice compared with ATRAID KO mice ( Supplementary Fig. 3m ). Histomorphometric measures of osteoclast function including osteoclast surface per bone surface (Oc.S/BS) 51 , as judged by Tartrate Acid Resistant Phosphatase TRAP staining 52 , were also unchanged ( Supplementary   Fig. 3n ). Consistent with basal defects in osteoblast function, ATRAID KO mice have reduced serum levels of circulating Gla-Osteocalcin (Gla-OC; the activated form of OC, incorporated in bone matrix 53 ) and modestly reduced bone formation rate (BFR) as measured by doublelabeling 51 ( Supplementary Fig. 3o , p).
To test the effect of alendronate in a model that mimics menopausal bone loss, the most common indication for the N-BPs, we performed ovariectomies (OVX) on adult female mice (Fig. 3a ) 54 . When ovaries are removed from females, the changes in estrogen cause a reduction in bone density triggered by disruption of the balance of osteoblast and osteoclast functions.
This loss of bone density can be alleviated by treatment with N-BPs 55 . The magnitude of trabecular bone loss in WT and ATRAID KO sham mice four weeks after OVX is exemplified in the µCT 3D reconstruction of the femoral proximal metaphysis (Fig. 3b) . In wild-type mice, we found decreased bone density as measured by femoral cortical and trabecular structural parameters, including cortical thickness and bone volume/trabecular volume (%), after OVX compared to the sham group, (Fig. 3c, d and Supplementary Fig. 3q , s, see WT +/-OVX) 55 .
Consistent with alendronate preventing bone loss, femoral structural parameters were increased by alendronate treatment of WT OVX mice ( Fig. 3b-d See WT OVX +/-alendronate). In contrast, alendronate had blunted effects in ATRAID KO OVX mice ( Fig. 3b-d and Supplementary   Fig. 3q , r, see ATRAID KO OVX +/-alendronate). The same patterns of resistance in ATRAID KO mice were observed for both bone strength and serum bone proteins ( Fig. 3e-i) . That is, alendronate increased bone strength as judged by stiffness and yield load and decreased biochemical markers of bone turnover, CTX-I and total osteocalcin (OC), in wild-type ovariectomized mice, but its effects were significantly blunted in ATRAID KO matched cohorts ( Fig. 3e-i) . Interestingly, the only parameter made worse by alendronate in wild-type mice was post-yield displacement (Fig. 3g) . Thus, this measurement, consistent with published literature 56, 57 , provides a correlate for the downside of taking N-BPs, namely that they might increase bone fragility. Importantly ATRAID loss prevented alendronate-mediated reduction in post-yield displacement (Fig. 3g) , which suggests that ATRAID might contribute to treatment outcome 58 .
Because N-BPs potentially affect osteoclasts and osteoblasts, we investigated whether ATRAID deficiency would regulate the effects of alendronate in each cell type in our osteoporosis model.
Regarding osteoclasts, in wild-type mice both osteoclast surface per bone surface (Oc.S/BS) and osteoclast number per bone surface (N.Oc/BS) were impaired by alendronate treatment (Fig. 3j, k) . In contrast, in ATRAID KO mice, alendronate was noticeably less effective on osteoclasts (Fig. 3j, k) . That osteoclast number was reduced by N-BPs in wild-type mice is consistent with our cell viability measurements in non-osteoclasts ( Fig. 1, 2 and Supplementary   Fig. 1 , 2) and with previous literature 55 .
To provide insight into the effects of N-BPs on osteoblasts in our osteoporosis model, we measured BFR and mineral apposition rate (MAR) 51 . Unlike BFR where the bone formation rate is normalized by the amount of labeled bone surface, MAR is the rate of bone formation irrespective of how much of the bone is active 51 . Alendronate did not affect trabecular MAR or BFR in either wild-type or ATRAID KO mice (Fig. 3l, m) suggesting that the osteoblast is not an important determinant of the alendronate-dependent improvements in the bone parameters we measured in our experimental paradigm.
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The ATRAID-dependent effects we observed of N-BPs on bone are consistent with the osteoclasts and not osteoblasts being a key cell type affected by N-BPs (Fig. 3) . As ATRAID is expressed well in osteoclast lineage cells ( Supplementary Fig. 4 ) 59 , we sought to test whether ATRAID functioned cell-autonomously in this cell type. First, we generated ATRAID knockout RAW 264.7 cells, a robust, well-characterized murine macrophage cell line (Fig. 4a ) that can be differentiated to osteoclast-like cells using RANKL 60 . ATRAID deficiency did not impair RAW 264.7 RANKL-induced differentiation (Fig. 4b) . This is consistent with our results in mice where basal measures of osteoclast function were not significantly reduced by ATRAID deficiency ( Supplementary Fig. 3m , n Fig. 4f) .
Furthermore, BMM-derived ATRAID KO osteoclasts were also resistant to alendronate-induced apoptosis (Fig. 4g ). This suggests that ATRAID is required cell autonomously in osteoclasts for the effects of N-BPs on cell number.
Alendronate did not affect known markers of osteoclast differentiation in wild-type cells (Fig. 4f) .
Therefore, to pursue the mechanism of its cell-autonomous effects on osteoclast function, we focused on prenylation. In alendronate-treated RAW 264.7 and differentiated RAW 264.7 to osteoclast cells, we found ATRAID KO cells were resistant to alendronate-induced inhibition of prenylation (Fig. 4h) . In total, these findings suggest that ATRAID is required for the cellautonomous effects of N-BPs on prenylation in its key target cell type -the osteoclast.
The focus of this work has been on ATRAID as a novel factor upstream of FDPS in a genetic pathway with N-BPs, heretofore the Target of Bisphosphonates (TBONE) pathway (Fig. 4i) . This work has focused on prenylation as an output of FDPS function, but recently FDPS has been linked to DNA synthesis and damage 40 . Considering that ATRAID overexpression induces p53
and senescence 62 , it will be interesting to determine whether these effects are mediated by cDNA manipulations and mutagenesis. The cDNAs for ATRAID were cloned from a human R4 cell line cDNA library. For expression studies, all cDNAs were amplified by PCR and the products were subcloned into the Sal 1 and Not 1 sites of pRK5 or pMSCV 71 . The controls, metap2 and tubulin, were previously described 72 . All constructs were verified by DNA sequencing. To generate the 293T ATRAID_KO expressing ATRAID-FLAG, using Gibson assembly we cloned the cDNA encoding ATRAID with a C-terminal Flag tag into a homologous recombination vector targeting the AAVS1 locus. We transfected this vector along with pX330
expressing an sgRNA targeting the AAVS1 locus.
sgRNA manipulations. Genome editing experiments were designed based on an established protocol 73 . In brief, the sgRNAs for ATRAID were cloned using Golden Gate assembly into pSpCas9-BB-2A-GFP (PX438), a kind gift from Feng Zhang (Addgene #48138). Haploid genetic screening. The genetic selection with alendronate, simvastatin, and lovastatin was performed on 100 million mutagenized KBM7 cells 74 . Cells were exposed to 165 µM alendronate, 12 µM simvastatin, or 12 µM lovastatin and allowed to recover for 4 weeks before harvesting the surviving cells and isolating genomic DNA. Analysis of the screen was performed essentially as described previously 74 . In brief, the sequences flanking retroviral insertion sites were determined using inverse PCR followed by Illumina sequencing. After mapping these sequences to the human genome, we counted the number of inactivating mutations (i.e., mutations in the sense orientation or present in exon) per individual Refseq-annotated gene as well as the total number of inactivating insertions for all Refseq-annotated genes. For each gene, statistical enrichment was calculated by comparing how often that gene was mutated in the drug-treated population with how often the gene carries an insertion in the untreated control dataset. For each gene, the P-value (corrected for false discovery rate) was calculated using the one-sided Fisher exact test (Supplementary Table 1 ).
PubMed citation analysis.
We downloaded all PubMed citations via the repository:
https://github.com/maximilianh/pubMunch and NCBI aliases from the NCBI website, ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/GENE_INFO/Mammalia/, into separate MySQL database tables. We queried the abstracts for the co-occurrence of the three terms: for 1) <official human NCBI gene symbol>; 2) "GWAS" or "genome-wide" and; 3) <human tissue>. This combination of terms highly enriches for studies involving molecular biology and humans. We also performed natural language processing to exclude abstracts that contain gene symbols, e.g., with common
English words such as ACT as well as all "HLA-" containing gene symbols. To determine whether our alendronate haploid screen hit genes that were cited in studies focused on bone significantly more than would occur by chance, we randomly selected 20 control sets of 185 genes and performed a similar analysis to that with our 185 hit genes. CRISPRi genetic screening. Version 2 of the CRISPRi library was used and screens were performed as previously described 75 . The goal of these screens is to determine the extent to which a gene knockdown affects cell growth in the presence of the selection pressure, i.e., drug, (after normalizing by growth in the absence of drug). We used all drugs at a half-maximal inhibitory concentration (IC50) value 76 -a common measure of drug potency. After drug selection, high-throughput sequencing of DNA from treated and untreated cells was performed to identify genes which when inactivated alter cell growth rate most significantly. Two biological replicates were used for each of the three conditions: T0, untreated, and treated. The sequencing analysis pipeline source code is available here:
https://github.com/mhorlbeck/ScreenProcessing. Statistical significance is based on the concept of the false discovery rate 77 . We employed formulas for deriving cellular phenotypes from cell fraction measurements in a population at discrete time-points 78 .
For Transcriptional profiling analysis. The multiple myeloma, osteonecrosis of the jaw (ONJ) microarray gene expression was performed using Affymetrix U133 Plus 2.0 array platform (Affymetrix, Santa Clara, CA, USA) as previously described 41 . 21 multiple myeloma patients with a history of N-BP use were included in the study. 11 patients (52.4%) reported to have ONJ.
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The breast cancer bone marrow micrometastases microarray gene expression data also used the Affymetrix U133 Plus 2.0 array platform. 54 breast cancer patients treated with zometa (zolendronate) were included in the study. 14 patients (25.9%) eventually died and 40 patients (74.1%) survived. Her-2 negative patients were divided into two categories following randomization to the zolendronate arm: those that who had DTC reoccurrences or lived less than 1000 days and those who lived at least 2500 days.
Quantile normalization was used for all differential expression analysis, and all the normalization procedures were performed using function normalizeQuantiles in the R Bioconductor package limma 79 . Gene expression data was filtered using function filterfun in the R Bioconductor package genefilter 80 . Probes with expression values over 5 in less than 25% of the samples were removed. Comparison between groups were estimated using an empirical Bayes method 81 , and variances across all genes were used to estimate the variance of each gene.
Raw p-values were calculated from a moderate t-test, and false discovery rate (FDR) adjusted p-values were obtained based on Benjamini and Hochberg's methods for multiple testing. Log 2 fold changes between the experimental conditions were calculated for each gene as well.
Affy probe IDs were transformed into gene symbols based on the R Bioconductor package, hgu133plus2.db 82 . In Fig. 1i Animal procedures. Age and sex matched mice were randomly assigned to treatment groups within each genotype. All animal experiments were replicated two to four times spanning independent days to ensure reproducibility.
Ovariectomy or sham operations were performed on 3.5-month-old females as detailed previously 88 . Briefly, the ovaries were exposed through an abdominal approach and either resected after clipping the blood vessels or left in place (sham operation). The muscle and skin of the abdomen were sutured. Mice were given an intraperitoneal injection of buprenex immediately after surgery and then every twelve hours for 48 hours post-surgery. Immediately 30 preceding OVX, vehicle (phosphate buffered saline) or 100 μg/kg alendronate (both provided by Sigma) was injected intra-peritoneally every week for 4 weeks. These doses were chosen based on the anti-resorptive activity of alendronate in different species 89, 90 .
Bone microstructure. A high-resolution desktop micro-tomographic imaging system (µCT40, Scanco Medical AG, Bruttisellen, Switzerland) was used to assess cortical and trabecular bone microarchitecture and morphology in the femoral mid-diaphysis and distal metaphysis, respectively. Scans were acquired using a 10 µm 3 isotropic voxel size, 70 kVP peak x-ray tube potential, 114 mAs x-ray intensity, 200 ms integration time, and were subjected to Gaussian filtration and segmentation. Regions of interest (ROIs) were selected 50 slices above and below the femoral longitudinal midpoint or 100 slices above the growth plate of the distal femur to evaluate the cortical and trabecular compartment, respectively. Image acquisition and analysis adhered to the JBMR guidelines for the use of µCT for the assessment of bone microarchitecture in rodents 48 .
Bone biomechanics. Mechanical testing in a 3-point bending to failure was conducted on femora after µCT. Briefly, hydrated femora were stabilized over supports 7mm apart and a loading force was applied in the anteroposterior direction midway between the supports (Instron, Norwood, MA, USA). Test curves were analyzed to determine ultimate force to failure and stiffness as described previously 49, 91 .
Bone histomorphometry. To label mineralizing fronts, mice were injected intraperitoneally with calcein (15 mg/kg i.p., Sigma-Aldrich) and alizarin red (30 mg/kg; Sigma) were intraperitoneally injected 7 and 2 days, respectively, before euthanasia. Bone was fixed in 10%(vol/vol) neutral buffered formalin for 24 h, processed through a series of graded alcohols, and decalcified.
Decalcified vertebrae or femurs were embedded in paraffin and 2-4 h, processed through a series of graded alcohols, and Tartrate resistant acid phosphatase (TRAP) stain was performed.
Undecalcified femora were embedded in methyl methacrylate and the whole bone were cut and stained for TRAP or analyzed for calcein and alizarin red fluorescence. Quantitative histomorphometry was performed using a commercial software (OSTEO II, Bioquant, Nashville, TN, USA), and standard parameters of bone remodeling were determined as detailed elsewhere 92 .
Statistics analysis. Unless otherwise specified, group means were compared by one-tailed 
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